Skip to main content

Advertisement

Table 3 Comparison of the parameters of lipid and glucose metabolism, hepatic function and muscle damage in the diet therapy and diet-plus-statin groups

From: Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia

  Diet Diet-plus-statin
  Baseline 6 months 12 months Baseline 6 months 12 months
Lipid metabolism:      
 TC (mg/dL) 211 ± 6 220 ± 9 201 ± 6 207 ± 7 171 ± 5**† 157 ± 5**††
 LDL-C (mg/dL) 139 ± 6 139 ± 7 126 ± 5 136 ± 6 94 ± 4**† 83 ± 4**††
 HDL-C (mg/dL) 56 ± 3 57 ± 4 56 ± 4 56 ± 4 61 ± 5 57 ± 5
 TG (mg/dL) 145 ± 14 198 ± 33 149 ± 21 154 ± 20 132 ± 19 122 ± 18
Glucose metabolism:      
 Glucose (mg/dL) 113 ± 7 108 ± 4 115 ± 7 107 ± 4 108 ± 4 115 ± 9
 HbA1C (%) 5.6 ± 0.1 5.6 ± 0.2 5.5 ± 0.2 5.6 ± 0.1 5.7 ± 0.1 5.6 ± 0.2
Hepatic and muscle enzymes:     
 AST (U/L) 24 ± 1 27 ± 2 27 ± 2 20 ± 1† 26 ± 5 22 ± 2
 ALT (U/L) 22 ± 2 25 ± 2 24 ± 3 20 ± 3 29 ± 8 26 ± 6
 CK (U/L) 110 ± 13 128 ± 20 161 ± 54 106 ± 13 131 ± 24 114 ± 16
  1. Values are means ± SE. TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglyceride, AST aspartate transaminase, ALT alanine transaminase, CK creatine kinase. **P < 0.001 vs baseline; †P < 0.05, ††P < 0.001 vs diet therapy alone